TapewireFind a company

person · Reporting owner

Spiess Bernhard E.

Disclosed activity across 1 company

Tapewire entity
132413
SEC CIK
0001782994

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CASTLE BIOSCIENCES INCCSTL · Entity 359Chief Business OfficerDecember 10, 2021December 15, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CASTLE BIOSCIENCES INC

Report date December 10, 2021 · Filed December 15, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,696 Ending reported balance After 2021-12-10 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2021-12-10 · Exercise / conversion · Acquired 1,500 · Balance 15,062

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Row 2 · 2021-12-10 · Tax withholding · Disposed 366 · Balance 14,696

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect4,500 Reported balance After 2021-12-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2021-12-10 · Exercise / conversion · Disposed 1,500 · Balance 4,500

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 10, 2021 Filed Dec 15, 2021 01:00 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionRestricted Stock Units · Derivative 1,500 $0.00 $0.00
Disclosure

SEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · derivative · entry 3

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 1,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021.

F2 · derivative.expiration_date: On December 10, 2020, the Reporting Person was granted 6,000 RSUs, which vest in four equal annual installments beginning on December 10, 2021.

Read SEC document
December 10, 2021 Filed Dec 15, 2021 01:00 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Tax withholdingCommon Stock 366 $40.52 $14,830.32
Disclosure

SEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,696

Read SEC document
December 10, 2021 Filed Dec 15, 2021 01:00 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 1,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001447362-21-000270 · wf-form4_163952998240535.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,062

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 6,412 $0.00 Strike: $2.39 $0.00
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · derivative · entry 7

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,304

Underlying: Common Stock · 6,412 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F6 · derivative.exercise_date: 25% of the 12,305 shares originally subject to the option vested on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 8,989 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · derivative · entry 6

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,889

Underlying: Common Stock · 8,989 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F5 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 1,474 $77.29 $113,925.46
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 5

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,562

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F4 · price: This transaction was executed in multiple trades at prices ranging from $76.70 to $77.63, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,889 $76.14 $448,388.46
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 4

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,036

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F3 · price: This transaction was executed in multiple trades at prices ranging from $75.60 to $76.45, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 8,038 $75.24 $604,779.12
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 3

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,925

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

F2 · price: This transaction was executed in multiple trades at prices ranging from $74.59 to $75.58, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 6,412 $2.39 $15,324.68
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

Read SEC document
September 02, 2021 Filed Sep 7, 2021 21:26 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 8,989 $1.92 $17,258.88
Disclosure

SEC source: 0001447362-21-000213 · wf-form4_163104995353264.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,551

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 19, 2021.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:06 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 8,989 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · derivative · entry 3

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,878

Underlying: Common Stock · 8,989 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021.

F3 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:06 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 8,989 $70.00 $629,230.00
Disclosure

SEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,562

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:06 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 8,989 $1.92 $17,258.88
Disclosure

SEC source: 0001447362-21-000130 · wf-form4_162335918644795.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,551

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 24, 2021.

F2 · balance_after: Includes 1,815 shares acquired on February 26, 2021 under the Issuer's employee stock purchase plan.

Read SEC document
December 10, 2020 Filed Dec 14, 2020 19:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantRestricted Stock Units · Derivative 6,000 $0.00 $0.00
Disclosure

SEC source: 0001447362-20-000289 · wf-form4_160797283348524.xml · derivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSUs vest in four equal annual installments beginning on December 10, 2021.

F3 · derivative.expiration_date: The RSUs vest in four equal annual installments beginning on December 10, 2021.

Read SEC document
December 10, 2020 Filed Dec 14, 2020 19:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantStock option (right to buy) · Derivative 23,000 $0.00 Strike: $59.16 $0.00
Disclosure

SEC source: 0001447362-20-000289 · wf-form4_160797283348524.xml · derivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,000

Underlying: Common Stock · 23,000 shares

Expires 2030-12-09

F1 · derivative.exercise_date: 25% of shares shall vest on December 10, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Read SEC document
December 01, 2020 Filed Dec 3, 2020 21:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 40,000 $49.97 $1,998,800.00
Disclosure

SEC source: 0001447362-20-000270 · wf-form4_160702964050490.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,747

F1 · price: This transaction was executed in multiple trades at prices ranging from $49.68 to $50.08, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
September 09, 2020 Filed Sep 10, 2020 20:11 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 15,000 $49.80 $747,000.00
Disclosure

SEC source: 0001447362-20-000213 · wf-form4_159976867970562.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,747

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020.

Read SEC document
September 08, 2020 Filed Sep 9, 2020 20:03 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 14,888 $49.00 $729,512.00
Disclosure

SEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 3

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,747

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020.

Read SEC document
September 04, 2020 Filed Sep 9, 2020 20:03 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 5,112 $49.00 $250,488.00
Disclosure

SEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,635

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020.

Read SEC document
September 04, 2020 Filed Sep 9, 2020 20:03 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 20,000 $47.00 $940,000.00
Disclosure

SEC source: 0001447362-20-000207 · wf-form4_159968177654132.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,747

F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020.

F2 · balance_after: Includes 1,121 shares acquired under the Issuer's employee stock purchase plan on August 31, 2020.

Read SEC document
August 19, 2020 Filed Aug 21, 2020 20:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 20,000 $45.00 $900,000.00
Disclosure

SEC source: 0001447362-20-000189 · wf-form4_159804042475133.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,626

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 18, 2020.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 20:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 400 $38.94 $15,576.00
Disclosure

SEC source: 0001447362-20-000101 · wf-form4_159130122788334.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,626

F2 · price: This transaction was executed in multiple trades at prices ranging from $38.93 to $38.95, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
June 02, 2020 Filed Jun 4, 2020 20:07 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 SaleCommon Stock 31,833 $38.18 $1,215,383.94
Disclosure

SEC source: 0001447362-20-000101 · wf-form4_159130122788334.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,026

F1 · price: This transaction was executed in multiple trades at prices ranging from $37.93 to $38.92, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
May 08, 2020 Filed May 12, 2020 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionStock option (right to buy) · Derivative 32,233 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0001447362-20-000055 · wf-form4_158931513579119.xml · derivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,867

Underlying: Common Stock · 32,233 shares

Expires 2026-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the 169,592 shares originally subject to the option vested on May 2, 2017, and the remaining shares vested in 36 equal monthly installments thereafter.

Read SEC document
May 08, 2020 Filed May 12, 2020 20:25 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 Exercise / conversionCommon Stock 32,233 $1.92 $61,887.36
Disclosure

SEC source: 0001447362-20-000055 · wf-form4_158931513579119.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 13, 2019 Filed Dec 17, 2019 21:12 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 GrantStock option (right to buy) · Derivative 35,000 $0.00 Strike: $29.50 $0.00
Disclosure

SEC source: 0001447362-19-000024 · wf-form4_157661715881831.xml · derivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2029-12-12

F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:24 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionConvertible Promissory Note · Derivative Not disclosed Not disclosed Strike: $12.80 $20,000.00
Disclosure

SEC source: 0001209191-19-043858 · doc4.xml · derivative · entry 4

Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,619 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F2 · reported_value: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F2 · price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F2 · derivative.exercise_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

F2 · derivative.expiration_date: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:24 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionSeries F Preferred Stock · Derivative 6,872 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043858 · doc4.xml · derivative · entry 3

Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,637 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F1 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:24 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionCommon Stock 1,619 $12.80 $20,723.20
Disclosure

SEC source: 0001209191-19-043858 · doc4.xml · nonDerivative · entry 2

Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The principal amount of the Convertible Promissory Note held by the designated Reporting Person was $20,000. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share.

Read SEC document
July 29, 2019 Filed Jul 31, 2019 20:24 UTC CASTLE BIOSCIENCES INC CSTL · Entity 359 ConversionCommon Stock 5,637 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-043858 · doc4.xml · nonDerivative · entry 1

Spiess Bernhard E. · CIK 0001782994 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,718

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.